In patients with high-risk, inoperable early-stage NSCLC, adding atezolizumab to SBRT did not improve overall survival vs SBRT alone (HR 1.04; 2-year OS 82% in both groups). The trial closed for futility. Grade ≥3 adverse events were 12% vs 3%.
RCTn = 417
Daly et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial